Article Sidebar
Published:
May 25, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Tetrazole exerts anti-hepatitis effect in mice via activation of PI3K/Akt pathway, inhibition of cell autophagy and suppression of inflammatory cytokine expressions
Abstract
Purpose: To investigate the effect of tetrazole on concanavalin A (Con A)-induced hepatitis in mice, and the underlying mechanism(s).
Methods: Thirty 5-week-old, male BALB/c mice (mean weight, 30.5 ± 1.04 g) were used for this study. They were randomly assigned to six groups of five mice each: control group, hepatitis group and four treatment groups. With the exception of control group, hepatitis was induced in all mice with Con A (20 mg/kg) via their tail veins. The treatment groups received varied doses of tetrazole (1.0 - 6.0 mg/kg) within 1 h after hepatitis induction, while mice in the control group received an equivalent volume of normal saline in place of tetrazole. Serum activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined while expressions of interleukin-2 (IL-2), tumor necrosis factor ߙ) TNF-ߙ ,(and interferon gamma (IFN-ߛ (were evaluated by enzyme-linked immunosorbent assay (ELISA) kits. Expressions of protein kinase B (Akt), phosphoinositide 3-kinase (PI3K), nuclear transcription factor- ߢB (NF-ߢB), and autophagy-related genes were determined by real-time quantitative polymerase chain reaction (qRT-PCR) and Western blotting.
Results: Con A-induced hepatitis significantly increased the activities of serum ALT and AST in the mice. However, after treatment with tetrazole, the activities of these enzymes were significantly and dose-dependently reduced in the treatment groups, relative to hepatitis group (p < 0.05). The levels of IL-2, IFN-ߛ and TNF-ߙ were significantly increased in hepatitis group when compared with the control group (p < 0.05). However, treatment with tetrazole significantly inhibited the expressions of these parameters. There were no significant differences in the levels of expressions of Akt mRNAs among the treatment groups (p > 0.05). The levels of expressions of LC3II and Beclin 1 were also significantly upregulated in hepatitis group, when compared with control group (p < 0.05). However, expression levels of LC3II and Beclin 1 were significantly and dose-dependently reduced by tetrazole treatment
Conclusion: Tetrazole is effective in the treatment of hepatitis via mechanisms involving the activation of PI3K/Akt pathway, inhibition of cell autophagy and suppression of inflammatory cytokines expressions.
